A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol

INTRODUCTION: There are currently no effective treatments preventing conversion from mild cognitive impairment (MCI) to Alzheimer's disease. Cilostazol is a selective type-3 phosphodiesterase inhibitor that ameliorates accumulation of amyloid-β and has prevented cognitive decline in rodent mode...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Dement (N Y)
Main Authors: Saito, Satoshi, Kojima, Shinsuke, Oishi, Naoya, Kakuta, Ryosuke, Maki, Takakuni, Yasuno, Fumihiko, Nagatsuka, Kazuyuki, Yamamoto, Haruko, Fukuyama, Hidenao, Fukushima, Masanori, Ihara, Masafumi
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2016
Assuntos:
Featured Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651350/
https://ncbi.nlm.nih.gov/pubmed/29067312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.10.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados